Nonmedical Uses of Antibiotics: Time to Restrict Their Use?

Meek, Richard W.; Vyas, Hrushikesh; Piddock, Laura J. V.

doi:10.1371/journal.pbio.1002266

Cited by 116 publications

(81 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The new NP and P pharmacophores are derived from porphyrin (phase-II; exeporfinium (27) (50), which is part of a combination with meropenem (43) called Carbavance. Although these classes have been classified as synthetically-derived for this review, they are inspired by the NP clavulanic acid, which was the first β-lactamase inhibitor reported.…”

Section: New Antibacterial Pharmacophore Analysismentioning

confidence: 99%

“…17 A range of reviews and discussions on the antibiotic crisis were published over the past two years. These include articles on the antibiotic crisis [18][19][20][21][22] and possible solutions, 23,24 sources of resistance, 25 surveillance of resistance, 26 restricting non-medical antibiotic use, 27 antibiotic resistance in livestock and the environment, 28,29 possible approaches to address R&D and commercialization challenges, [30][31][32] difficulties in discovering new antibiotics, 33 development of new antibiotics, [34][35][36] reviews of therapeutic strategies 37 and new approaches to discover novel antimicrobials 38,39 to combat antibiotic resistance.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antibiotics in the clinical pipeline at the end of 2015

2016

View full text Add to dashboard Cite

There is growing global recognition that the continued emergence of multidrug-resistant bacteria poses a serious threat to human health. Action plans released by the World Health Organization and governments of the UK and USA in particular recognize that discovering new antibiotics, particularly those with new modes of action, is one essential element required to avert future catastrophic pandemics. This review lists the 30 antibiotics and two β-lactamase/β-lactam combinations first launched since 2000, and analyzes in depth seven new antibiotics and two new β-lactam/β-lactamase inhibitor combinations launched since 2013. The development status, mode of action, spectra of activity and genesis (natural product, natural product-derived, synthetic or protein/mammalian peptide) of the 37 compounds and six β-lactamase/β-lactam combinations being evaluated in clinical trials between 2013 and 2015 are discussed. Compounds discontinued from clinical development since 2013 and new antibacterial pharmacophores are also reviewed.

show abstract

Section: New Antibacterial Pharmacophore Analysismentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Antibiotics in the clinical pipeline at the end of 2015

2016

View full text Add to dashboard Cite

show abstract

“…[3][4][5][6][7][8] However, the extent to which these sources contribute to the development, emergence and spread of AMR is not yet quantified. [9] Without this critical, system-wide knowledge it is impossible to effectively optimise and target interventions.…”

Section: Current Situationmentioning

confidence: 99%

Addressing the Unknowns of Antimicrobial Resistance: Quantifying and Mapping the Drivers of Burden

Knight

Costelloe

Murray

et al. 2017

Clinical Infectious Diseases

View full text Add to dashboard Cite

Telephone:(+44) 20 3313 1283Key points: To tackle antimicrobial resistance, we need first to quantify and map its drivers. In this viewpoint, we propose a detail three key action areas that desperately require systems mapping approach to do this, attention: the mapping of sources and transmission routessupported by comprehensive, data collection and novel quantification analysis.. AbstractThe global threat of antimicrobial resistance (AMR) has arisen through a network of complex interacting factors. Many different sources and transmission pathways contribute to the ever-growing burden of AMR in our clinical settings. The lack of data on these mechanisms and the relative importance of different factors causing the emergence and spread of AMR hampers our global efforts to effectively manage the risks. Importantly, we have little quantitative knowledge on the relative contributions of these sources and are likely to be targeting our interventions suboptimally as a result.Here we propose a systems mapping approach three major actions to address the urgent need for reliable and timely data in order to strengthen the response to AMR.

show abstract

“…At the global level, this goal has been partially addressed through restricting non-medical use of antibiotics [75] and, in the clinical setting, through antibiotic stewardship programs [76]. For individual patients, proper use of antibiotics requires the optimal design of dosing protocols and drug combinations.…”

Section: Treatmentsmentioning

confidence: 99%

Quantitative and synthetic biology approaches to combat bacterial pathogens

Bethke

Wang

et al. 2017

Current Opinion in Biomedical Engineering

View full text Add to dashboard Cite

Antibiotic resistance is one of the biggest threats to public health. The rapid emergence of resistant bacterial pathogens endangers the efficacy of current antibiotics and has led to increasing mortality and economic burden. This crisis calls for more rapid and accurate diagnosis to detect and identify pathogens, as well as to characterize their response to antibiotics. Building on this foundation, treatment options also need to be improved to use current antibiotics more effectively and develop alternative strategies that complement the use of antibiotics. We here review recent developments in diagnosis and treatment of bacterial pathogens with a focus on quantitative biology and synthetic biology approaches.

show abstract

Nonmedical Uses of Antibiotics: Time to Restrict Their Use?

Cited by 116 publications

References 36 publications

Antibiotics in the clinical pipeline at the end of 2015

Antibiotics in the clinical pipeline at the end of 2015

Addressing the Unknowns of Antimicrobial Resistance: Quantifying and Mapping the Drivers of Burden

Quantitative and synthetic biology approaches to combat bacterial pathogens

Contact Info

Product

Resources

About